Zymeworks nabs $350M from Jazz Pharmaceuticals after release of clinical trial data

Following a positive release of clinical data from a phase 2b testing trial of zanidatamab, Zymeworks, based in the Pacific Northwest, has secured $350 million from Jazz Pharmaceuticals.

Jazz Pharmaceuticals plans to commercialize zanidatamab, a leading drug for a second-line treatment for HER2-positive biliary tract cancer. The drug will be sold across the U.S., Europe and Japan.

READ THE STORY at GeekWire »